VERICI DX PLC (VRCI) — Interim Results

Investor webinar replay

Replay transcript excerpt

Good morning, and welcome to the VERICI DX PLC interim results investor presentation. Throughout this quarter presentation, investors will be in listen only mode. Questions are encouraged, they can be submitted at any time by the q and a tab situated at the right hand corner of your screen. Simply type in your questions and press send. The company may not be in a position to answer every question received in the meeting itself. Have the company can view the questions submitted today and publish responses where it's appropriate to do so. Before we begin, I'd like to submit the following poll. I'd now like to hand you over to CEO, Sarah Barrington. Good morning. Good morning, everybody. And I will just move the slides. Thank you. Just was once welcome everybody to, the interim road show, for the first half of twenty twenty five, and also a follow-up meeting, after our financing event, which, closed two months ago. So just as a quick reminder about who VERICI is, we are a kidney transplant company, with three products, two of which converged, commercialized. And we are at a pivotal point that the last financing was enabling us to move from a milestone based company into a commercial growth company. We are moving forward on on that. So the company has raised 37,500,000, sterling to date to walk through the, the the all the milestones to get to commerciality. And we have two products, and we'll go through the products in in due course. But the, most recent milestone that we were waiting to achieve, which we did in April of this year, was to gain, coverage from Medicare on our lead products, to Tymia. I'm going to just move forward on that. Just as a reminder about our products, we have three. They're all based on, RNA based technology, and they answer, distinct clinical q...